XNPT stopped heart burn drug trial:PPS is $5.92 now!
XenoPort to stop development of heartburn drug
Related News
* UPDATE 1-Gene therapy shows promise for Parkinson's
Wed, Mar 16 2011
* UPDATE 2-Novartis sees blood cancer drug as blockbuster
Tue, Mar 15 2011
* UPDATE 3-Dendreon gets FDA OK to quadruple Provenge capacity
Thu, Mar 10 2011
* New lupus drug may end treatment nightmare for some
Thu, Mar 10 2011
XenoPort Inc
XNPT.O
$5.89
-0.78-11.69%
12:28pm EST
AstraZeneca PLC
AZN.L
2,853.00p
+25.00+0.88%
12:29pm EST
Glaxosmithkline Plc
GSK.L
1,153.50p
+11.50+1.01%
12:29pm EST
Mon Mar 21, 2011 9:21am EDT
(Reuters) - XenoPort Inc (XNPT.O) will stop development of its experimental drug to treat heartburn after it failed to meet the main goal of a mid-stage trial, sending its shares down 12 percent in pre-market trading.
The company was developing the drug, arbaclofen placarbil, as a combination therapy for people who suffer from gastroesophageal reflux disease (GERD), but do not get complete relief from the medicines that doctors currently prescribe to treat it.
A class of drugs called proton pump inhibitors, or PPIs, such as AstraZeneca's (AZN.L) Nexium and Prilosec are the current standard of care for patients with GERD.
News 
Market Data 
Discover 
AI
